SLU-PP-332

A university-lab "exercise mimetic" (Saint Louis University, hence the name) — an ERR pan-agonist that increased endurance and fat oxidation in 2023-24 mouse papers. SLU-PP-915 is a follow-on compound.

SLU-PP-332 activates the estrogen-related receptors, a family of nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism. Despite the name they are not oestrogen receptors and do not respond to oestrogen — a genuinely confusing piece of nomenclature that matters here, because the compound is sometimes discussed as though it had hormonal effects it does not. In mice, activating them shifted metabolism toward fat oxidation and increased running endurance, which is the entire basis of its reputation as the newest "exercise mimetic".

A handful of mouse studies from one research group, published within the last three years. No published or registered human study was found as of August 2026; pharmacokinetics and toxicity in people are guesswork.

• NONE. There is no human trial of SLU-PP-332 of any size or phase. It has never entered clinical development.
• The evidence is a small body of mouse work from the academic group that developed it, reporting increased endurance and metabolic effects.
• It appeared in the research-chemical market almost immediately after the animal papers were published — faster than any meaningful safety characterisation could occur, which is the pattern this category repeats.
• The receptors it targets regulate mitochondrial function throughout the body, not only in muscle. What sustained activation does elsewhere in a person has not been examined.
• Sold as research-chemical supply of unverified identity, concentration and purity.

Human pharmacokinetics have never been characterised — no bioavailability, half-life or clearance figure exists for people, and any number in circulation is animal extrapolation or invention. The animal work used administration routes and amounts that do not translate directly to a person taking a powder.

Compounds this new have no case-report literature because not enough time has passed for harms to surface and be written up. ERRs regulate cardiac metabolism among much else — "it does a lot of things in a lot of tissues" is the risk statement.

• Everyone — zero human data of any kind, sold before any safety characterisation existed
• Anyone pregnant or breastfeeding
• Anyone in tested sport, where metabolic modulators are prohibited

• No characterised human interaction profile exists.
• Anything affecting mitochondrial function or metabolic rate, on mechanistic grounds rather than evidence.

• There is no established monitoring for a compound with zero human data, and offering a panel would imply a characterisation that does not exist.
• The honest position: nobody has measured what this does in a person, at any exposure, over any duration.

Nothing is known about stopping because nothing is known about taking it. No withdrawal syndrome is described and no established effect exists to lose.

US: not FDA-approved for human use; unscheduled.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications
  Rev Med Chil, 2026
• In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential
  Rapid Commun Mass Spectrom, 2026
• An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
  J Pharmacol Exp Ther, 2026

• A Synthetic ERR Agonist Alleviates Metabolic SyndromeJ Pharmacol Exp Ther · 2024
• Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial FunctionCirculation · 2024
• In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping PotentialRapid Commun Mass Spectrom · 2026
• An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacityJ Pharmacol Exp Ther · 2026
• Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signalingInt J Biol Macromol · 2026
• Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise CapacityACS Chem Biol · 2023
• Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control PurposesDrug Test Anal · 2026
• Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging KidneyAm J Pathol · 2023
• [Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications]Rev Med Chil · 2026
• Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot studyFront Physiol · 2025